Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Ahmed Elaileh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5824-9472; OpenAlex author ID A5000141656. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. Co-author DOI 10.1016/j.jss.2026.02.012↗
  2. Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? Co-author DOI 10.1097/coc.0000000000000661↗
  3. Promising new treatments for pancreatic cancer in the era of targeted and immune therapies. Co-author PMID 31598392↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashish Saharia · 3 shared papers, 2019–2026 · strength 0.45
  2. Maen Abdelrahim · 3 shared papers, 2019–2026 · strength 0.45
  3. Kirk Heyne · 3 shared papers, 2019–2026 · strength 0.45
  4. Kelvin Allenson · 1 shared paper, 2026 · strength 0.23
  5. Nestor F. Esnaola · 1 shared paper, 2026 · strength 0.23
  6. Ahmed Osama Gaber · 1 shared paper, 2026 · strength 0.23
  7. Ashton Anthony Connor · 1 shared paper, 2026 · strength 0.23
  8. Youssef E. Dib · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.